INTRODUCTION

The demographic shift in the human population reflects an aging society—over 20% of Europeans are predicted to be 65 or over by the year 2025 (Riera & Dillin, 2015). Aging is the major risk factor for developing chronic diseases, such as cancer, Alzheimer’s disease, and cardiovascular complications (Partridge et al., 2018). Unfortunately, humans spend on average one-fifth of their lifetime in poor health suffering from one or multiple age-related chronic diseases (Partridge et al., 2018). However, the onset of age-related pathologies is not fixed, and the rate of aging was shown to be mal- leable. The goal of biomedical research on aging or geroscience is to identify interventions that compress late-life morbidity to increase the period spent healthy and free from disease.
A few geroprotective drugs exist that postpone age-related diseases (Riera & Dillin, 2015). For instance, the anti-diabetes drug metformin reduces age-related chronic diseases and mortality from all causes (Bannister et al., 2014). Ongoing clinical trials on geroprotective drugs or compounds include the anti-diabetic drugs metformin (NCT02432287, NCT03451006) and acarbose (NCT02953093); mTOR-inhibiting and immunosuppressant drug rapamycin (sirolimus; NCT02874924); natural compounds resveratrol (NCT01842399) and urolithin A (NCT04160312); and nicotinamide adenine dinucleotide precursors NR (NCT02950441) and NMN (NCT04685096). One primary outcome measure used in the aforementioned clinical trials for metformin and acarbose is the restoration from an "old" to a "youthful" gene expression signature (NCT02432287, NCT02953093). Therefore, we reasoned that cross-comparing youthful expression signatures against expression profiles elicited by small molecules could identify geroprotective compounds. Conceptually similar in silico approaches have been conducted in the past (Aliper et al., 2016; Calvert et al., 2016; Dönertaş et al., 2018, 2019; Fuentealba et al., 2019; Janssens et al., 2019; Komljenovic et al., 2019; Liu et al., 2016). However, these former approaches comparing age-related expression profiles with drug-treated cells revealed similar drug targets (Dönertaş et al., 2019), such as the HSP90/HSF-1 axis (Fuentealba et al., 2019; Janssens et al., 2019). Our strategy was to use a more refined starting list of a "youthful" gene expression signature with experimentally implicated genes associated with healthy aging.

A key signature of aging is the continuous decline of collagen and cell adhesion gene expression (Ewald, 2019; Magalhães et al., 2009) accompanied with an increase in matrix metalloproteinase expression (Ewald, 2019). Gene expression ontologies of extracellular matrix (ECM) genes have been associated with healthy aging in humans (Zeng et al., 2020). The ECM not only embeds cells and tissues but also provides instructive cues that change cellular function and identity. For instance, placing old cells into a "young" ECM rejuvenates senescent cells or stem cells and even reprograms tumor cells (reviewed in Ewald, 2019). Moreover, collagen homeostasis is required and sufficient for longevity in Caenorhabditis elegans (Ewald et al., 2015). Heparan/chondroitin biosynthesis and TGFβ pathway are frequently enriched in C. elegans longevity drug screens (Liu et al., 2016). Collectively, these functionally implicated genes are all members of the matriome.

The human matriome encompasses 1027 protein-encoding genes that either form the ECM, such as collagens, glycoproteins, and proteoglycans; associate with ECM (e.g., TGFβ, Wnts, and cytokines); or remodel the ECM (e.g., matrix metalloproteinases (MMPs)) (Naba et al., 2016). The matriome represents about 4% of the human genome and is functionally implicated in about 8% of the total 7037 unique human phenotypes (Statzer & Ewald, 2020). Age-related phenotypes rank among the top matriome-phenotypic categories across species (Ewald, 2019; Taha & Naba, 2019). Proteomics approaches have revealed unique ECM compositions associated with health and disease status (Socovich & Naba, 2019). ECM compositions can even be used to identify distinct cancer-cell types (Ewald, 2019). Therefore, organismal phenotypes, physiological states, and cellular identity are characterized by distinct sets of expressed ECM proteins. Since these unique ECM compositions are an expression profile on a temporary, sometimes local basis and do not involve the entire matriome, we coined the term matriotype (Ewald, 2019). The matriotype is the acute state of an ECM composition associated with— or causal for— a given physiological condition or phenotype (Ewald, 2019). Given the functional implication of ECM in healthy aging, we hypothesized that a youthful matriotype might predict drugs promoting healthy aging. Here, we define a youthful human matriotype using data from the Genotype-Tissue Expression (GTEx) project (Consortium, 2013). We query this young matriotype signature with the drug resource Connectivity Map (CMap) (Lamb et al., 2006) data to identify longevity-promoting compounds. We then developed a novel in vivo tool as a surrogate marker for longevity to find appropriate drug doses to be used for C. elegans’ lifespan assays. Our results implicate previously known longevity drugs as well as novel drugs, providing a proof-of-concept for our approach.

2 | RESULTS

2.1 | Geroprotective compounds associated with altering ECM

We first performed literature and database mining to search for compounds that have been shown to increase lifespan and are known to alter ECM in any organism. We acquired lifespan data from databases DrugAge and GeroProtectors (Figure 1a) (Barardo et al., 2017; Moskalev et al., 2015). We filtered for reported mean lifespan extensions that were above 5% for compounds compared to control (Figure 1a; Table S1)— then queried all PubMed abstracts for the given agent and our ECM key terms, including collagen, MMP, proteoglycan, integrin, and TGFβ (Figure 1a; Table S1). After manual curation, we identified 3% (16 out of 567) of the examined known longevity-promoting compounds that slow aging and also had been reported to affect proteins outside of cells, such as collagens and other matriome proteins (Figure 1b; Table S1).

2.2 | Longevity compounds affect matriome gene expression

Next, we investigated whether compound treatments, in general, would alter matriome expression. Connectivity Map (CMap) is a library of 1.5 million gene expression profiles comparing 1309 different compound treatments on human cell cultures (Lamb et al., 2006). We queried the CMap library for compound treatments that either increase or decrease the expression levels of matriome genes. Using a z-score threshold of ±1.5, we identified 167 compounds that strongly regulate the 594 out of the 1027 matriome genes compared to the background (13,752 total quantified genes; Figure 2a, Figure S1, Table S2). Out of the 12 most up- and 12 most downregulated
matrisome expression profiles upon a compound treatment, we identified ten agents linked to longevity or impairment of age-related pathologies (Figure 2b,c, Table S2). Strikingly, out of these 47 known longevity-promoting compounds that were assessed in the CMap library, we found 41 (87%) significantly altered matrisome gene expression (Figures S2–S4, Table S2). After manual curation, we identified 20 additional compounds reported to increase lifespan. From the total 67 reported lifespan-increasing compounds, 19 had minor effects on overall matrisome gene expression, whereas 26 compounds increased, and 22 decreased, matrisome gene expression (Figure 2a, Table S2). These results suggest that compounds implicated in healthy aging show enriched differential matrisome gene expression.

2.3 | Defining young and old human matreotypes

For a more targeted approach, we reasoned that using a young age-associated matrisome gene expression signature (i.e., youthful
matrisome regulation: downregulated  not regulated  upregulated

-2.0  -1.5  -1.0  -0.5  0.0  0.5  1.0  1.5  2.0

(a)

(b)

(c)

Relative expression

-4.0  -3.5  -3.0  -2.5  -2.0  -1.5  -1.0  -0.5  0.0  0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0

(p values: $p < 2.22 \times 10^{-16}$)

-2.5  0.0  2.5  5.0  7.5

levonorgestrel  medrysone  phthalylsulfathiazole  ginkgolide A

diphenhydramine  nadolol  viomycin  adiphenine

meclofenoxate  medrysone  metamizole  sodium  phthalylsulfathiazole

flunixin  ginkgolide A  GW6510  tracazolate  riflusal  X0175029.0000  azaguanine

sulfadimethoxine  thiamphenicol  rimethobenzamide  ev

merbromin  atractyloside  iphenhydramine  lisuride

Z-score

(c)
matreotype) to query CMap data should reveal more compound treatments that might promote longevity. To define a young and old human matreotype, we built upon the previous analysis of the GTEx dataset ( Consortium, 2013 ) comparing a young versus an old gene expression pattern of more than 50 tissues and 8000 transcriptomes by Janssens and colleagues ( Janssens et al., 2019 ). From these 50 tissues, we only identified 15 tissues that had on average 138 age-related transcripts per tissue, which we then filtered for matrisome genes ( Figures S5, S6, Table S3 ). In our analysis, we used two different approaches to quantify age-related transcript changes: the difference in expression ( "absolute" ) and the fraction of change ( "relative" ). The absolute expression change preferentially captures genes exhibiting high baseline expression levels, since any change in their abundance translates to a large absolute change. By contrast, the relative expression difference quantifies the change to the previously measured value and favors lower expressed genes.

Among these age-related transcripts, matrisome genes were well-represented: collagen gene expression decreased with age, while matrix proteases ( MMPs, ADAMs ) increased ( Figure 3a–d, Table S3 ). These findings were consistent with previous reports ( Ewald, 2019 ; Magalhães et al., 2009 ). However, we noted a number of key observations. First, each tissue has a unique age-related matreotype gene expression signature ( Figures S5, S6, Table S3 ). Second, both the transcript coverage and the age association of the matrisome varies within the 15 assessed tissues. Therefore, we decided to narrow the focus of our study to five tissues: skin, thyroid, pituitary, aorta, and coronary artery tissue ( Figure S7, Table S3 ). In the remaining tissues, the number of age-associated transcripts was too low to quantify the contribution of the matrisome conclusively. Third, certain matrisome genes, such as GDF15, experienced both increasing and decreasing expression levels during aging, depending on the tissue ( Figure 3b ). With these observations in mind, our aim was to construct a multi-tissue compendium of matrisome members, which were most affected by aging.

To extend the matreotype generated from these five tissues, we combined the findings of eight studies that also included transcriptomes across ages from different tissues in order to validate and identify additional multi-tissue and age-related matrisome genes ( Table S3 ). By considering both absolute and relative aging gene expression changes, we determined the age-related matreotype of brain, fat, skin, and other tissues to generate a new common signature across tissues ( Figure S8, Table S3 ). By inverting the aged expression pattern, we defined the age-reversed or "youthful" matreotype ( Table S4 ). Using this approach, we defined here, for the first time, a multi-tissue compendium of 99 genes across 15 human tissues, which we define as the young and aged matreotype.

### 2.4 Use of the young and aged matreotype to identify new pro-longevity compounds

The ultimate goal of our matreotype signature is its application to identify new geroprotective compounds that modulate the matrisome, and thus, longevity. To first validate this approach, we used known pro-longevity compounds and identified those causing a youthful matreotype ( i.e. , similar gene expression; Figure 4, Tables S4, S5 ). We parsed the youthful matreotype signature into "down-regulated matreotype genes that become upregulated during aging" ( Figure 4a ) and "upregulated matreotype genes that become down-regulated during aging" ( Figure 4b, Table S4 ). We queried the CMap compound expression profiles and plotted the top 50 compounds that showed the gene expression signature as predicted by the youthful matreotype and called them "reversed aging signature" compounds ( Figure 4a,b ). As a control, we also plotted the top 50 compounds that would enhance gene expression in the direction-ality of aging and called them "potentiated aging signature" compounds ( Figure 4a,b ). Of these total 200 compounds, 15 compounds were identified with both youthful and aged matreotypes, leaving 185 unique compounds.

Next, we searched the literature for reported lifespan increase in any organism upon treatment with any of these 185 compounds and found 24 of these compounds resulted in lifespan extension ( Figure 4, Table S5 ). To our surprise, these 24 compounds with reported lifespan increase did not cluster preferentially with the "reversed aging signature" compounds as predicted but rather were almost equally distributed among all categories ( Figure 4 ). This suggests that at least for matrisome genes, longevity might not be a simple reversion of gene expression associated with aging. Or it might be more complex given that each tissue has a unique matreotype ( Figures S5–S7 ), such as that seen with GDF15 ( Figure 3 ). Despite this unexpected finding, we note that our matreotype-99-gene-compendium was able to identify 185 unique compounds, of which 13% have previously been reported to extend lifespan ( Figure 4 ). This is an improvement compared to the 5% of the 67 longevity-promoting compounds found in all 1309 CMap assessed small molecules ( Figure 2a ). Thus, independent of directionality, both youthful and age-related matreotype, that is, the matreotype signature itself predicts longevity-promoting drugs.

### 2.5 Validating matreotype-predicted compounds with lifespan assays using C. elegans

To translate the in-silico analysis to an in-vivo functional relevance for healthy aging, lifespan assays in model organisms, such as C. elegans or mice, are commonly used. The limitation of these lifelong assays, especially in mice, is that often one does not know if the optimal dose is applied until the end of the study 3 years later. To overcome this
limitation, we developed an in-vivo screening assay measuring collagen biosynthesis. Similar to humans, collagen biosynthesis declines with age in C. elegans, and we recently discovered that many, if not all, longevity interventions prolong the expression of collagen genes in C. elegans (Ewald et al., 2015). This prolonged expression of key collagen genes is required and sufficient for longevity (Ewald et al., 2015). Thus, we hypothesized that prolonged collagen expression, quantified on the transcriptional level by a collagen promoter-driven GFP, would constitute a useful surrogate marker to predict longevity (Figure 5a). Indeed, we found that the GFP intensity driven by collagen col-144 promoter (Pcol-144::GFP) declined almost linearly within the first 5 days of adulthood (Figure 5b, Table S6).

To validate our hits, we chose eleven compounds out of 194 matreotype-predicted hits and examined a single compound dose

FIGURE 3 Matrisome genes affected by aging across human tissues. (a–b) Absolute (a) and relative (b) expression changes of all detected genes during aging are shown. Matrisome genes are displayed in red and non-matrisome genes in black. (c–d) Absolute (c) and relative (d) expression changes of only detected matrisome genes during aging are shown and are colored by tissue. For details, see Table S3.
FIGURE 4 Matreotype signature gene expression correlating with CMap expression pattern. (a–b) Matreotype genes that are strongly upregulated (a) or downregulated (b) during aging are hierarchically clustered with gene expression patterns of small molecules on human cell lines from CMap library (Table S4). Black rectangles indicate that the respective compound increases lifespan in any organism (Table S5).
for examining the Pcol-144::GFP expression levels during aging. We found that vitamin B12 (cyanocobalamin), chrysos, and dapsone maintained strong Pcol-144::GFP expression at old age (Figure 5c, Table S6). Therefore, we decided to assess these concentrations of B12, chrysos, and dapsone, and found that they robustly increased lifespan (Figure 5d, Table S7). This indicates the usefulness of this reporter to identify a longevity-promoting dose for C. elegans lifespan validation.

In our youthful matrotype-associated drugs, we have identified phenformin (Figure 4b, Figure S9, Table S2), an analog of metformin. Both phenformin and metformin have been shown to increase C. elegans lifespan (Pryor & Cabreiro, 2015). Here, we found that treating late L4 C. elegans with metformin, prolonged collagen expression in a dose-dependent manner (Figure 5e; Figure S10, Table S6). This is consistent with a study showing metformin slows extracellular matrix morphological decline of the cuticle (Haes et al., 2014). This suggests that one unexplored aspect of the metformin’s mechanism of action might be via improved collagen homeostasis. Given this exciting finding, we decided to prioritize our investigations into drugs that will enhance collagen homeostasis in mammals but have not shown any pro-longevity phenotypes in any organisms. We, therefore, chose to test the retinoic acid receptor agonist tretinoin since tretinoin treatment prevents MMP upregulation and stimulates collagen synthesis in photo-aged skin (Griffiths et al., 1993; Mukherjee et al., 2006). Our analysis showed that tretinoin had an enriched differential expression of matrisome genes (Figure S9). Furthermore, tretinoin has been predicted to associate with a youthful expression pattern by the in-silico analysis of Janssens and colleagues but did not increase C. elegans lifespan at 50 μM (Janssens et al., 2019). With our reporter system, we found that treatment with 10 μM of tretinoin prolonged collagen expression and increased lifespan (Figure 5f–i; Figure S10, Tables S6, S7), confirming that tretinoin indeed promotes healthy aging.

Following the same rationale, in our drug hits that change matrisome expression, we identified genistein, an isoflavone (phytoestrogen) derived from soybeans to have a youthful matrotype profile (Figure S9). Genistein has been predicted to associate with a youthful expression pattern by a previous in-silico analysis but failed to increase C. elegans lifespan at 50 μM (Janssens et al., 2019). By contrast, other groups reported a lifespan increase using 50 and 100 μM genistein (Lee et al., 2015). To reconcile this, we generated new 98% pure genistein and found prolonged collagen expression in aged C. elegans and a mild increase in lifespan (Figure 5j, Figure S11, Table S7). To optimize drug uptake, we encapsulated genistein extracts with liposomes. We found higher collagen protein content in aged C. elegans (day 8 of adulthood), enhanced oxidative stress resistance during older age (day 5 adults), and improved lifespan extension compared to empty vector liposomal control treatments (Figure 5k,l, Figures S11–S12, Tables S7–S8). A similar strategy was used to encapsulate royal jelly oil in a lecithin-based nanoemulsion for improved solubility on the NGM culturing plates to facilitate uptake by C. elegans (Figures S10, S11). These data indicate that optimizing drug delivery and dose is important for lifespan and healthspan benefits.

To expand our findings, we searched for compounds that could alter ECM composition and were not included in the CMap library. Besides collagens, glycoprotein and proteoglycans are the other two major components of ECMs across species (Naba et al., 2016; Teuscher et al., 2019). We decided to investigate ECM precursors, such as glucosamine, chondroitin sulfate, and hyaluronic acid, which are part of the sugars added to these ECM proteins as potential mediators of the youthful matrotype. In humans, cohort studies of over 70–500 thousand participants who took glucosamine or chondroitin supplements showed a 15%–18% and 22% reduction in total mortality, respectively (Bell et al., 2012; Li et al., 2020). Here, we found that glucosamine treatment increased collagen expression during aging (Figure S10, Table S6). Previous studies also implicated glucosamine supplementation in lifespan extension of C. elegans and mice (Weimer et al., 2014). Using our collagen reporter screening system, we determined that 20 μg/ml of hyaluronic acid and 400 μg/ml chondroitin sulfate prolonged collagen synthesis during aging and were sufficient to increase lifespan (Figure 5m–o; Figures S10, S12, Tables S6–S8). Thus, our ECM-transcriptional reporter system is a powerful tool to identify drug-response doses that promote healthy aging.

**FIGURE 5** Validating compounds that were predicted to modulate the age-related matrotype for in-vivo collagen expression and lifespan. (a) Heterogeneity in decline of collagen col-144 promoter-driven GFP (LSD2002 [Pcol-144::GFP]) at day 3 of adulthood. GFP levels were categorized in 4 groups (none/very low, low, medium, and high). (b) Approximately linear decline of Pcol-144::GFP expression during the first 5 days of adulthood. (c) A single concentration per matrotype-predicted compound tested for their efficacy on prolonging Pcol-144::GFP expression during aging. (d) Lifespan corresponding to the matrotype-predicted compounds with prolonged Pcol-144::GFP expression during aging. (e–f) Metformin (e) and tretinoin (f) were observed to partially prolong Pcol-144::GFP expression during aging in certain dosage regimes. (g–h) Representative image (g) and quantification (h) of Pcol-144::GFP expression at day 4 of adulthood upon tretinoin treatment from day 1 of adulthood. (i) Adulthood treatment (start at day 2 of adulthood) of tretinoin extended lifespan. (j) Adulthood treatment of genistein increased Pcol-144::GFP expression at day 4 of adulthood. (k) Liposomal-encapsulated genistein showed higher collagen over total protein levels at day 8 of adulthood. (l) Adulthood treatment (start at day 2 of adulthood) of liposomal-encapsulated genistein extended lifespan. (m) Adulthood treatment of chondroitin increased Pcol-144::GFP expression at day 4 of adulthood. (n) Adulthood treatment of hyaluronic acid increased Pcol-144::GFP expression at day 5 of adulthood. (o) Adulthood treatment (start at day 2 of adulthood) of chondroitin or hyaluronic acid extended lifespan. For raw data and statistics for (b, c, e, f, h, j, k, m, n), see Table S6. For raw data, statistics, and additional trials (d, i, l, o), see Table S7.

3 | DISCUSSION

Recent artificial intelligence, *in silico*, and other computational approaches have been harnessed to predict beneficial and longevity-promoting effects of compounds, which were previously not
considered to mediate effects on ECM gene expression. A major challenge lies in the validation of the health-promoting results of a compound. Here, we demonstrated that a concise list of 1027 matrisome or 99 matreotype genes facilitates the identification of lifespan-enhancing drugs. To establish a proof-of-concept for our matreotype approach, we developed a new non-invasive and in-vivo reporter system, which we used to validate known and novel geroprotective drugs. We used our system to determine the appropriate dose to unravel the compounds’ longevity potential indicated with our, and previous, in-silico approaches.

Established geroprotective drugs, such as metformin, rapamycin, resveratrol, and others, with known lifespan-extending effects, have previously been reported to alter the expression of ECM components (Figure 1). When we compared gene expression signatures, we found that almost ninety percent of the known longevity-promoting compounds in the CMap library showed changes in matrisome gene expression. To identify novel geroprotective drugs, we refined our approach by parsing ECM gene signatures resembling a young or aged matreotype to correlate with a given drug’s gene expression pattern. We found 185 candidate drugs, of which 24 showed lifespan increase in model organisms and 42 unique compounds had previously been predicted as potential geroprotectors (Table S5).

The generally accepted assumption is that there is a drift in gene expression during aging, and that restoration of a younger gene expression pattern indicates rejuvenation of cells or tissues. This premise has been extensively used as a biomarker for the restoration of health in clinical trials (NCT02432287, NCT02953093), parsing healthy versus common aging cohorts (Zeng et al., 2020), reprogramming cells into a younger state (Lu et al., 2020), or in previous in-silico approaches (Tyshkovskiy et al., 2019). This premise also requires that longevity or rejuvenating interventions work through temporal scaling, a process that has been shown to be the case for lifespan extension and aging-associated gene expression in C. elegans (Stroustrup et al., 2016; Tarkhov et al., 2019) but not yet for mammals. We found that longevity-promoting drugs either increase or decrease matrisome gene expression (Figure 2). With a more refined approach using the youthful matreotype, we observed that both reversing or propagating the aging gene signatures could predict geroprotective drugs (Figure 4). One explanation could be that there is overlap in the gene expression signatures during aging and chronic diseases are similar (Zeng et al., 2020).

Clearly, independent of directionality, the current defined age-related matreotype holds predictive power to identify new lifespan-enhancing drugs. A shortcoming of our definition of the aging- and youth-associated expression signatures is that we do not take the context of the individual tissues into consideration. Unfortunately, insufficient studies are available to compile high-quality subsets for each tissue, which should be addressed in further experimental investigations. This is especially important in the case of collagen expression at an advanced age that can be both associated with improved tissue maintenance as observed in the skin and joints, while at the same time be implicated in fibrotic changes in the liver and kidney. For instance, downregulation of ECM in fat tissue but not in blood vessels is a key gene signature for healthy elderly individuals (Zeng et al., 2020). During aging, inflammation increases leading to fibrosis (Ewald, 2019). On the contrary, collagen synthesis declines during aging and degradation or fragmentation by increased MMP activities, evident in aging skin (Ewald, 2019). Several drugs, including rapamycin (Chung et al., 2019), tretinoin (Griffiths et al., 1993; Mukherjee et al., 2006), genistein (Polito et al., 2012), and resveratrol (Lephart & Andrus, 2017), increase collagen synthesis in the skin. By contrast, resveratrol, rapamycin, and genistein suppress fibrotic collagen deposition by intestinal fibroblasts, kidney, and lung tissues, respectively (Chen et al., 2012; Li et al., 2014; Matori et al., 2012). Thus, drugs might act as a geroprotector and increase lifespan by either inhibiting or enhancing the matrisome expression depending on pre-existing tissue damage or disease.

The model organism C. elegans does not show inflammation nor fibrosis during aging. Thus, collagen expression in C. elegans might reflect restoration or repair of the progressive decline of ECM homeostasis during aging analogous to human skin. This makes C. elegans the ideal readout for any age-dependent changes of matrisome genes observed from human or mammalian omics approaches. Based on this, we established an age-dependent collagen transcriptional read-out as a predictive marker for longevity.

In previous work, more than 100,000 compounds have been screened, and about 100 compounds have been identified to increase C. elegans lifespan (Table S5). A practical limitation in verifying drug candidates is the uncertainty in optimal dosage levels. Usually, one dose is chosen for all compound treatments for C. elegans lifespan screening assays, potentially leading to many false-negative results and limiting its interpretation. Dose-response curves are not linear, but often J- or U-shaped, whereby in general, high doses are toxic and low doses lead to hormetic responses increasing lifespan. We showed that two previously predicted but regarded as false-positive compounds—tretinoin and genistein—robustly increase lifespan when assayed at the appropriate dosage. Furthermore, optimization for the route of uptake improves robustness, promoting healthy aging. Thus, our reporter system serves as a predictive tool to identify the appropriate dosage for lifespan assays.

It is striking that longevity-promoting compounds identified in model organisms showed enriched matrisome gene expression signature in human cells treated with these compounds (Figures S2–S4). The proposed mechanisms for longevity compounds discovered with C. elegans mostly work through intercellular communication. Pathway analysis showed an enrichment for chondroitin and heparan sulfate biogenesis and TGFβ pathway as predicted drug-protein targets (Liu et al., 2016). On the contrary, the outcome of previous in-silico approaches using youthful gene expression determined from GTEx data to query CMap identified HSP90 chaperone network (Dönertas et al., 2019; Fuentesalba et al., 2019; Janssens et al., 2019) and protein homeostasis (Komljenovic et al., 2019) as healthy aging promoting interventions. HSP90 is found in the extracellular space binding fibronectin and chaperones other ECM proteins (Hunter et al., 2014). Pharmacological inhibition of HSP90 alters ECM signaling (Chaturvedi et al., 2011). Proper ECM protein homeostasis
is essential to ensure intercellular communication, a hallmark lost during aging (Ewald, 2019). This raises the question whether geroprotective drugs improve ECM homeostasis. There is tantalizing evidence with established longevity-promoting medications, such as rapamycin, resveratrol, metformin, and others (Figure 1b), and we provided experimental evidence for this with tretinoin, genistein, glucosamine, chondroitin, and hyaluronic acid (Figure 5). Consistent with this is that glucosamine and chondroitin stimulate collagen synthesis in vitro and ex vivo of elderly human skin in a clinical trial (Gueniche & Castiel-Higounenc, 2017; Lippiello, 2007), extracellular matrix component hyaluronic acid treatments stimulate collagen synthesis in human photo-aged skin (Wang et al., 2007), and in mice (Fan et al., 2019), and topical application of rapamycin restores collagen VII levels in a clinical trial (NCT03103893) (Chung et al., 2019). ECM homeostasis might remodel or prevent glycation and crosslinking of collagens (Ewald, 2019). There are currently 27 clinical trials addressing ECM stiffness and its role in diseases by investigating eleven different molecular targets. Furthermore, different matreotypes might be valuable prognostic factors or biomarkers (Ewald, 2019). Thus, defining matreotypes related to healthy aging or age-related chronic diseases might be a strategy for personalized medicine approaches.

In summary, we demonstrated that prolonged ECM expression is a biomarker for C. elegans longevity and harnessed this to establish a novel in-vivo assay. We provided evidence that gene expression patterns of human cells treated with known geroprotective drugs alter ECM genes and developed an age-stratified matreotype. We then used this matreotype to identify geroprotective compounds based on their transcriptomes. Our method highlights a previously unused potential of ECM reprogramming as a means to identify and validate compounds, licensed drugs, natural compounds, and supplements that potentially retard or prevent age-related pathologies. Understanding pharmacological reprogramming of extracellular environments may provide a new platform to discover previously unidentified therapeutic avenues and holds significant translational value for disease diagnostics.

4 EXPERIMENTAL PROCEDURE

4.1 Strains

*Caenorhabditis elegans* strains were maintained on NGM plates and OP50 *Escherichia coli* bacteria. The wild-type strain was N2 Bristol. Mutant strains used are described at www.wormbase.org: TJ1060: *spe-9(hc88) I; rrf-3(b26) II*. LSD2002 was generated by integrating Pcol-144::GFP transgene (a generous gift from Yelena Budovskaya and Stuart Kim) into N2, outcrossing eight times, and crossing to TJ1060, resulting *spe-9(hc88) I; xhls001 [Pcol-144::GFP; pha-1(+) X* genotype.

4.2 Data analysis

Data analysis was performed utilizing the *dplyr* (Hadley Wickham, Romain François, Lionel Henry and Kirill Müller (2020). *dplyr: A Grammar of Data Manipulation. R package version 1.0.0*) and *purr* (Lionel Henry and Hadley Wickham (2020). *purr: Functional Programming Tools. R package version 0.3.4*). *R* packages. Data visualization was generated using *ggplot2* (H. Wickham. *ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics), and *ggpubr* (Alboukadel Kassambara (2020). *ggpubr: "ggplot2" Based Publication Ready Plots. R package version 0.4.0.999).

4.3 Data origin

Human matrisome (http://matrisomeproject.mit.edu, (Naba et al., 2016)), GTEx data (Consortium, 2013), age change (Janssens et al., 2019). CMap data (Lamb et al., 2006), lifespan information were obtained from GenAge. Geroprotectors (Moskalev et al., 2015), and through a comprehensive literature review.

4.4 Literature search

Compounds that extended the mean lifespan of the organism by more than 5%, according to the DrugAge (Barardo et al., 2017) and Geroprotector (Moskalev et al., 2015) databases, were selected for further investigation. The abstracts of studies associated with lifespan extension were filtered for the occurrence of at least one of the following matrisome keywords: collagen, ECM, extracellular, matrix, proteoglycan, hyaluronic, hyaluronan, TGF, integrin, and TGFbeta.

4.5 Aging matreotype definition

To define the human aging matreotype, we performed a literature search and extracted the age association of all genes involved in forming the human matrisome. The inclusion criteria for the meta-analysis require whole-genome coverage for each study, availability of the full dataset including negative data, and that the publication has undergone peer-review. If the datasets have not yet been subjected to a significance cutoff, we applied multiple testing corrected (Benjamini–Hochberg) threshold of 0.05 to each dataset if applicable. Tissue-specific differences were not further investigated due to confounding in the meta-analysis. Studies analyzing individual tissues were treated as separate sources. To define the aging matrisome, we acquired data from at least three sources implicating the gene in the aging process. Studies that offer directionality were further utilized to determine matrisome genes that were upregulated or downregulated with age using the same thresholds.

4.6 Collagen promoter-driven GFP scoring

The strain LSD2002 Pcol-144::GFP was used to assess age-related decline in collagen-144 expression. Animals were age-synchronized
by bleaching and made infertile by cultivating at 25°C. NGM culturing plates were prepared with tretinoin (Sigma PHR1187), hyaluronic acid (Sigma H5388), chondroitin sulfate (Sigma 27042), metformin (Sigma D150959), glucosamine (Sigma G4875), and genistein (Changzhou Longterm Biotechnology Co., Ltd). Distribution scoring is based on intensity observed visual inspection, categorizing to none or very low, low, medium, or high intensity. For some experiments, animals were mounted onto 2% agar pads and pictures were taken with an upright fluorescent microscope (Tritech Research, model: BX-51-F). To separate the GFP signal from the autofluorescence of the gut, we used the microscope, settings, and triple-band filterset as described by Teuscher (Teuscher & Ewald, 2018). The total intensity per animal, intensity [a.u.], is calculated from fluorescence images using FIJI. The detailed instruction and workflow are described in Supplementary File 1 and the python code in Supplementary File 2.

4.7 | Lifespan measurements

Manual scoring of lifespan as previously described by Ewald et al. (2016). In brief, about 100 day-2 adult C. elegans were picked to NGM plates containing the solvent either water or 0.1% dimethyl sulfoxide (DMSO) alone as control or tretinoin (Sigma PHR1187), hyaluronic acid (Sigma H5388), and chondroitin sulfate (Sigma 27042). Vitamin B12 (Sigma, PHR1234), chrysirin (Santa Cruz Biotech, sc-204686), and dapsone (Santa Cruz Biotech, sc-203023A) lifespans were performed in 1.25% DMSO and 50 µM FUdR in 24-well plates, 4 wells per condition and 30 worms per well, transferred at L4 developmental stage. Animals were classified as dead if they failed to respond to prodding. Exploded, bagged, burrowed, or animals that left the agar were excluded from the statistics. The estimates of survival functions were calculated using the product-limit (Kaplan–Meier) method. The log-rank (Mantel–Cox) method was used to test the null hypothesis and calculate P values (JMP software v.14.1.0).

Additional Information can be found in the Extended Experimental Procedure in the Supporting Information available online.

ACKNOWLEDGEMENT
We thank Anne Häfke for help with analyzing GFP expression, Katharina Tarnüfer for help with the hydroxyproline collagen measurements, Alina Teuscher for LSD2002 strain, and Sarah Jayne Mitchell and Michael Robert Mac Arthur for critical reading commenting on the manuscript. Some strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440). EJ was funded by a grant of the Mibelle Group Biochemistry, Mibelle AG, Switzerland. Funding from the Swiss National Science Foundation PP00P3_163898 to CYE and CS.

CONFLICT OF INTEREST
The authors have no competing interests to declare. Correspondence should be addressed to C. Y. E. The authors declare no conflict of interest. FW and FZ are employees of Mibelle Biochemistry.

AUTHOR CONTRIBUTIONS
All authors participated in analyzing and interpreting the data. CYE and CS designed the experiments. CS established and performed in-silico analysis. AD and PM translated compound names for list comparison and automated analysis. EJ, CS, AD, and CYE performed lifespan assays. EJ and CYE performed oxidative stress assays. EJ, AD, and SXL performed collagen expression assays. FW and FZ prepared and encapsulated compounds. CYE wrote the manuscript in consultation with the other authors.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available in GTEx at https://gtexportal.org/home/datasets and CMap ftp://ftp.broadinstitute.org/distribution/cmap and adopted from reference https://doi.org/10.1016/j.celrep.2019.03.044. Further data were derived from the following resources available in the public domain: http://matrisomeproject.mit.edu, https://genomics.senescence.info/genes/, http://geroprotectors.org. All sources and processed/re-analyzed data are provided in Supplementary Tables in this study.

ORCID
Collin Y. Ewald https://orcid.org/0000-0003-1166-4171

REFERENCES
Aliper, A., Belikov, A. V., Garazha, A., Jellen, L., Artemov, A., Sunstova, M., Ivanova, A., Venkova, L., Borisoj, N., Buzdin, A., Mamoshina, P., Putin, E., Swick, A. G., Moskalev, A., & Zhavoronkov, A. (2016). In search for geroprotectors: In silico screening and in vitro validation of signalone-level mimetics of young healthy state. Aging, 8, 2127–2152. https://doi.org/10.18632/aging.101047
Bannister, C. A., Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, Obesity & Metabolism, 16, 1165–1173. https://doi.org/10.1111/dom.12354
Barardo, D., Thornton, D., Throppil, H., Walsh, M., Sharifi, S., Ferreira, S., Anžič, A., Fernandes, M., Monteiro, P., Grum, T., Cordeiro, R., De-Souza, E. A., Budovsky, A., Araujo, N., Gruber, J., Petrascheck, M., Fraifeld, V. E., Zhavoronkov, A., Moskalev, A., & de Magalhães, J. P. (2017). The DrugAge database of aging-related drugs. Aging Cell, 16, 594–597. https://doi.org/10.1111/acet.12585
Bell, G. A., Kantor, E. D., Lampe, J. W., Shen, D. D., & White, E. (2012). Use of glucosamine and chondroitin in relation to mortality. European Journal of Epidemiology, 27, 593–603. https://doi.org/10.1007/s10654-012-9714-6
Calvert, S., Tacutu, R., Sharifi, S., Teixeira, R., Ghosh, P., & de Magalhães, J. P. (2016). A network pharmacology approach reveals new candidate caloric restriction mimetics in C. elegans. Aging Cell, 15, 256–266.
Chaturvedi, V., Kumar, J. U., Paitthanking, K. R., Vanathi, P., & Sreedhar, A. S. (2011). Pharmacological inhibition of Hsp90 as a novel antitumor strategy to target cytoarchitecture through extracellular matrix signaling. Medicinal Chemistry, 7, 454–465.
Chen, G., Chen, H., Wang, C., Peng, Y., Sun, L., Liu, H., & Liu, F. (2012). Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One, 7, e33626. https://doi.org/10.1371/journal.pone.0033626
clinical efficacy and safety. Clinical Interventions in Aging, 1, 327–348. https://doi.org/10.2147/cia.2006.1.4.327

Naba, A., Clauser, K. R., Ding, H., Whittaker, C. A., Carr, S. A., & Hynes, R. O. (2016). The extracellular matrix: Tools and insights for the "omics" era. Matrix Biology, 49, 10–24. http://dx.doi.org/10.1016/j.matbio.2015.06.003

Partridge, L., Deelen, J., & Slagboom, P. E. (2018). Facing up to the global challenges of ageing. Nature, 561, 45–56. https://doi.org/10.1038/s41586-018-0457-8

Polito, F., Marini, H., Bitto, A., Irrera, N., Vaccaro, M., Adamo, E. B., Micali, N., Mosca, D., & Zoccali, C. (2015). Repurposing metformin: an old drug with new tricks in its binding pockets. Biochemical Journal, 471(3), 307–322. http://dx.doi.org/10.1042/bj20150497

Riera, C. E., & Dillin, A. (2015). Can aging be ‘drugged’?. Nature Medicine, 21(12), 1400–1405. http://dx.doi.org/10.1038/nm.4005

Socovich, A. M., & Naba, A. (2019). The cancer matrisome: From comprehensive characterization to biomarker discovery. Seminars in Cell & Developmental Biology, 89, 157–166. https://doi.org/10.1016/j.semcdb.2018.06.005

Statzer, C., & Ewald, C. Y. (2020). The in-silico characterization of the Caenorhabditis elegans matrisome and proposal of a novel collagen classification. Matrix Biology Plus, 1, 100001. http://dx.doi.org/10.1016/j.mbplus.2018.11.001

Tsykhovskiy, A., Bozaykut, P., Borodinova, A. A., Gerashchenko, M. V., Ables, G. P., Gerratt, M., Khaitovich, P., Clish, C. B., Miller, R. A., & Gladyshev, V. N. (2019). Identification and Application of Gene Expression Signatures Associated with Lifespan Extension. Cell Metabolism, 30(3), 573–593.e8. http://dx.doi.org/10.1016/j.cmet.2019.06.018

Wang, F., Garza, L. A., Kang, S., Varani, J., Orringer, J. S., Fisher, G. J., & Voorhees, J. J. (2007). In Vivo Stimulation of De Novo Collagen Production Caused by Cross-linked Hyaluronic Acid Dermal Filler Injections in Photodamaged Human Skin. Archives of Dermatological Research, 309(2), http://dx.doi.org/10.1001/archderm.143.2.155

Weimer, S., Priebes, J., Kuhlow, D., Groth, M., Priebe, S., Mansfeld, J., Merry, T. L., Dubuis, S., Laube, B., Pfeiffer, A. F., Schulz, T. J., Guthke, R., Platzer, M., Zamboni, N., Zarse, K., & Ristow, M. (2014). D-Glucosamine supplementation extends life span of nematodes and of ageing mice. Nature Communications, 5, 3563. https://doi.org/10.1038/ncomms4563

Zeng, L., Yang, J., Peng, S., Zhu, J., Zhang, B., Suh, Y., & Tu, Z. (2020). Transcriptome analysis reveals the difference between "healthy" and "common" aging and their connection with age-related diseases. Aging Cell, 19, e13121. https://doi.org/10.1111/acel.13121

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

[Correction added on 3 September 2021, after first online publication: Missed out Supplementary Tables has been included in this version.]

How to cite this article: Statzer, C., Jongsma, E., Liu, S. X., Dakhovnik, A., Wandrey, F., Mozharovskiy, P., Zülli, F., & Ewald, C. Y. (2021). Youthful and age-related matreotypes predict drugs promoting longevity. Aging Cell, 20, e13441. https://doi.org/10.1111/acel.13441